Back to Search
Start Over
Outcomes of kidney transplant recipients admitted to the intensive care unit: a retrospective study of 200 patients
- Source :
- BMC Anesthesiology, BMC Anesthesiology, Vol 19, Iss 1, Pp 1-9 (2019), BMC Anesthesiology, 2019, 19 (1), pp.130. ⟨10.1186/s12871-019-0800-0⟩
- Publication Year :
- 2019
- Publisher :
- Springer Science and Business Media LLC, 2019.
-
Abstract
- Background Risk of over-immunosuppression or immunization may mitigate the overall and long-term renal outcomes of kidney transplant recipients (KTR) admitted to the ICU in the modern era but remain poorly described. Thus, there is an unmet need to better characterize the survival of KTR admitted to the ICU, but also the renal and immunological outcomes of survivors. Methods Retrospective observational study that included 200 KTR admitted between 2010 and 2016 to the ICU of a teaching hospital (median age 61 years [IQR 50.7–68]; time from transplantation 41 months [IQR 5–119]). Survival curves were compared using the Log-rank test. Results Mortality rates following admission to the ICU was low (26.5% at month-6), mainly related to early mortality (20% in-hospital), and predicted by the severity of the acute condition (SAPS2 score) but also by Epstein Barr Virus proliferation in the weeks preceding the admission to the ICU. Acute kidney injury (AKI) was highly prevalent (85.1%). Progression toward chronic kidney disease (CKD) was observed in 45.1% of survivors. 15.1% of survivors developed new anti-HLA antibodies (donor-specific antibodies 9.2% of cases) that may impact the long-term renal transplantation function. Conclusions Notwithstanding the potential biases related to the retrospective and monocentric nature of this study, our findings obtained in a large cohort of KTR suggest that survival of KTR admitted in ICU is good but in-ICU management of these patients may alter both survival and AKI to CKD transition, as well as HLA immunization. Further interventional studies, including systematic characterization of the Epstein Barr virus proliferation at the admission (i.e., a potential surrogate marker of an underlying immune paralysis and frailty) will need to address the optimal management of immunosuppressive regimen in ICU to improve survival but also renal and immunological outcomes.
- Subjects :
- Male
Herpesvirus 4, Human
[SDV]Life Sciences [q-bio]
Cytomegalovirus
Virus Replication
law.invention
0302 clinical medicine
HLA Antigens
Isoantibodies
030202 anesthesiology
law
Neoplasms
Hospital Mortality
ComputingMilieux_MISCELLANEOUS
Mortality rate
Acute kidney injury
HLA immunization
Acute Kidney Injury
Middle Aged
Intensive care unit
Stroke
Intensive Care Units
Disease Progression
Female
France
Massive Hepatic Necrosis
Immunosuppressive Agents
Research Article
medicine.medical_specialty
Shock, Cardiogenic
Outcomes
Infections
lcsh:RD78.3-87.3
03 medical and health sciences
Internal medicine
medicine
Humans
Viremia
Renal Insufficiency, Chronic
Survival analysis
Aged
Retrospective Studies
Surrogate endpoint
business.industry
Renal transplantation
030208 emergency & critical care medicine
Retrospective cohort study
medicine.disease
Kidney Transplantation
Transplant Recipients
Transplantation
Anesthesiology and Pain Medicine
lcsh:Anesthesiology
business
Kidney disease
Subjects
Details
- ISSN :
- 14712253
- Volume :
- 19
- Database :
- OpenAIRE
- Journal :
- BMC Anesthesiology
- Accession number :
- edsair.doi.dedup.....3ec6eec77771d46e51c9ffbf53411fd2
- Full Text :
- https://doi.org/10.1186/s12871-019-0800-0